Chemistry:Fexuprazan

From HandWiki

Fexuprazan (trade name Fexuclue) is a drug for the treatment of gastroesophageal reflux disease (GERD).[1] It is a potassium-competitive acid blocker,[2] which is a class of drugs suppressing gastric acids.[3][4]

Fexuprazan is approved for clinical use in South Korea,[4][5] Mexico,[6] Philippines,[7] Chile,[8] and Ecuador.[9]

References

  1. ↑ "Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease". European Journal of Clinical Pharmacology 79 (8): 1023–1029. August 2023. doi:10.1007/s00228-023-03521-4. PMID 37344679. 
  2. ↑ "Efficacy and Safety of Fexuprazan in Patients with Acute or Chronic Gastritis". Gut and Liver 17 (6): 884–893. November 2023. doi:10.5009/gnl220457. PMID 36789577. 
  3. ↑ "Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans". Pharmaceutics 13 (6): 813. May 2021. doi:10.3390/pharmaceutics13060813. PMID 34072547. 
  4. ↑ 4.0 4.1 "Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans". Pharmaceuticals 15 (6): 709. June 2022. doi:10.3390/ph15060709. PMID 35745628. 
  5. ↑ "펙수클루정40밀리그램(펙수프라잔염산염)" (in Korean). https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=202108192. 
  6. ↑ "Daewoong Pharma's GER drug gets product OK from Mexico". Korea Economic Daily. October 19, 2023. https://www.kedglobal.com/bio-pharma/newsView/ked202310190002. 
  7. ↑ "Daewoong launches GERD treatment Fexuclu in Philippines" (in en). https://www.kedglobal.com/bio-pharma/newsView/ked202308010017. 
  8. ↑ "Daewoong wins approval for GERD treatment Fexuclu in Chile" (in en). Mar 14, 2023. https://www.kedglobal.com/bio-pharma/newsView/ked202303140013. 
  9. ↑ "Daewoong receives approval for its GERD drug Fexuclue in Ecuador" (in en). https://www.kedglobal.com/bio-pharma/newsView/ked202302060001. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Fexuprazan&oldid=4177981"